Significados de somatostatin analogue en inglés

The role of medical treatment with a somatostatin analogue should be emphasized.

Five patients had received somatostatin analogue.

This suggests that the presence of somatostatin receptors on human tumours does not automatically imply a beneficial effect of somatostatin analogue therapy.

An Italian prospective multicentre study evaluated the efficacy of octreotide, a synthetic somatostatin analogue, in preventing the complications of elective pancreatic surgery.

Lanreotide, another somatostatin analogue, became available in the mid-1990s initially as a prolonged-release formulation administered every 10 or 14 days.

Octreotide acetate is a somatostatin analogue that has been shown to ameliorate the side effects of excessive secretion of hormone from benign and malignant tumors.

The administration of somatostatin analogues or antacids is appropriate for symptom reduction.

Somatostatin analogues may therefore not be an effective therapy for obesity in PWS.

This review summarizes the development and clinical success of somatostatin analogues.

The patient was treated by somatostatin analogues then underwent liver transcatheter arterial chemo-embolization.

Endocrine therapy has become increasingly successful, with the development of dopamine agonists and somatostatin analogues.

There is a role for somatostatin analogues, especially in the setting of metastatic and symptomatic disease.

More work is therefore required to firmly establish the role of somatostatin analogues as potential antiangiogenic therapy.

Moreover, there is growing interest in the use of somatostatin analogues for the treatment of tumours with somatostatin receptors.

Previous retrospective studies have also suggested that surgical debulking of pituitary tumours causing acromegaly improves control by somatostatin analogues.

Larger chronic studies with long-acting somatostatin analogues will be needed to determine their benefits and risks in treating PWS obesity.